W.R. Berkley Corp’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

W.R. Berkley Corp’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,650	Closed	-$198K	–	332
2022 Q4	$198K	Hold	19,650	–	–	0.01%	331
2022 Q3	$195K	Hold	19,650	–	–	0.01%	496
2022 Q2	$192K	Hold	19,650	–	–	0.01%	536
2022 Q1	$191K	Hold	19,650	–	–	0.01%	553
2021 Q4	$190K	Hold	19,650	–	–	0.01%	546
2021 Q3	$191K	Hold	19,650	–	–	0.01%	429
2021 Q2	$190K	Buy	+19,650	New	+$193K	0.02%	351

W.R. Berkley Corp's EBAC Position: Q1 2023 in Review

W.R. Berkley Corp sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 19,650 shares — an estimated $198K sold.

W.R. Berkley Corp first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $198K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

W.R. Berkley Corp reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
W.R. Berkley Corp sold 19,650 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $198K.
W.R. Berkley Corp first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
W.R. Berkley Corp's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $198K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on W.R. Berkley Corp's 13F filing for Q1 2023, filed 15 May 2023.